Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension (“PAH”), announced today that ...

In phase 3 clinical trials, orforglipron was associated with significant reductions in mean percent body weight compared with placebo in patients with and without type 2 diabetes.

Detailed results from the phase 3 TEMPO trials show tavapadon offers a mechanistically distinct approach for managing motor ...

Following End-of-Phase 2 meeting, MBX remains on track to initiate Phase 3 in Q3 2026CARMEL, Ind., March 09, 2026 (GLOBE ...

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ('Inhibikase” or 'Company”), a clinical-stage pharmaceutical company developing ...

Defensive healthcare stocks such as Johnson & Johnson and CVS tend to outperform in recessions. Growth healthcare stocks ...

KERENDIA is a non-steroidal mineralocorticoid receptor antagonist (nsMRA) that selectively and potently blocks mineralocorticoid receptor overactivation in the heart and kidneys. 2 FIND-CKD is the ...

Hengrui Pharma (Hengrui), and Braveheart Bio today announced results from a multi-center, randomized, open-label Phase 2 dose-ranging study evaluating HRS-1893 (also known as BHB-1893), an ...

Structure Therapeutics' Phase 2 data for Aleniglipron show 16% weight loss at 44 weeks with strong tolerability and no safety ...

Shares of Xenon Pharmaceuticals (XENE) have gained approximately 20% over the past three months, primarily driven by positive top-line data from the X-TOLE2 study evaluating its lead candidate, ...

Biomea Fusion, Inc. ( BMEA) Discusses Menin Inhibition Mechanism and Therapeutic Potential in Diabetes March 30, 2026 3:00 PM EDT Michael J. Hitchcock - Interim CEO & Director Ramses Erdtmann - ...

Microsoft Defender for Endpoint is getting a new security recommendations that will help organizations boost their security posture in an increasingly dangerous world. Organizations running Microsoft ...